Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Other Income and Expenses [Abstract]
Interest income		$ (30)	$ (13)	$ (44)	$ (12)
Interest expense		293	316	614	651
Net interest expense		263	303	571	639
Royalty-related income		(217)	(212)	(389)	(388)
Net (gains)/losses on asset disposals		0	(58)	(1)	(98)
Net (gains)/losses recognized during the period on equity securities	[1],[2]	541	(800)	1,241	(1,200)
Income from collaborations, out-licensing arrangements and sales of compound/product rights	[3]	(5)	(21)	(14)	(252)
Net periodic benefit costs/(credits) other than service costs		295	(237)	12	(503)
Certain legal matters, net		19	24	98	74
Consumer Healthcare JV equity method (income)/loss	[4]	(149)	(140)	(334)	(202)
Other, net		26	(201)	(62)	(417)
Other (income)/deductions––net		$ 772	$ (1,343)	$ 1,122	$ (2,347)

[1] Reported in Other (income)/deductions––net. See Note 4.

[2] The losses in the second quarter and first six months of 2022 include, among other things, unrealized losses of $432 million and $776 million, respectively, related to investments in BioNTech and Cerevel Therapeutics Holdings, Inc. (Cerevel). The gains in the second quarter and first six months of 2021 included, among other things, unrealized gains of $917 million and $1.0 billion, respectively, related to investments in BioNTech and Cerevel.

[3] The first six months of 2021 included, among other things, $188 million of net collaboration income from BioNTech in the first quarter of 2021 related to Comirnaty.

[4] See Note 2C